Aikaterini Oikonomidi1, Domilė Tautvydaitė1, Mehdi M Gholamrezaee2, Hugues Henry3, Michael Bacher4, Julius Popp1. 1. Department of Psychiatry, Division of Old Age Psychiatry, University Hospital of Lausanne, Switzerland. 2. Department of Psychiatry, University Hospital of Lausanne, Switzerland. 3. Department of Laboratories, University Hospital of Lausanne, Switzerland. 4. Institute of Immunology, Philipps-University Marburg, Germany.
Abstract
BACKGROUND: Macrophage migration inhibitory factor (MIF) is a pro-inflammatory protein playing a regulatory role in the immune response. First evidence from in vitro and animal studies suggests that MIF may be involved in the development of Alzheimer's disease (AD) pathology. OBJECTIVE: To address in older subjects (i) the relationships between AD pathology and MIF plasma and cerebrospinal fluid (CSF) levels; and (ii) to investigate whether increased MIF-related systemic and CNS inflammation is associated with clinical disease progression. METHODS: CSF and plasma concentrations of MIF as well as biomarkers of amyloid, neuronal injury, and tau hyperphosphorylation (CSF Aβ1-42, tau, and ptau, respectively) were assessed in 97 subjects with MCI or mild dementia (cognitive impairment, CI) and 52 healthy volunteers with normal cognition. Clinical and neuropsychological evaluations were performed at inclusion and at follow up visits. RESULTS: CSF MIF levels were higher in participants with CI with an AD CSF biomarker profile, but not in CI with a non-AD profile, compared to the healthy controls. Higher MIF CSF levels were associated with higher CSF tau and ptau and lower CSF Aβ1-42 after adjusting for potential confounders. In CI, MIF CSF independently predicted cognitive decline at a follow-up visit after controlling for potential confounders including CSF Aβ1-42 and tau levels. CONCLUSION: Our study provides evidence that MIF-related inflammation is related to amyloid pathology, tau hyperphosphorylation, and neuronal injury at the early clinical stages of AD. Higher MIF CSF levels are associated with accelerated cognitive decline in MCI and mild dementia.
BACKGROUND:Macrophage migration inhibitory factor (MIF) is a pro-inflammatory protein playing a regulatory role in the immune response. First evidence from in vitro and animal studies suggests that MIF may be involved in the development of Alzheimer's disease (AD) pathology. OBJECTIVE: To address in older subjects (i) the relationships between AD pathology and MIF plasma and cerebrospinal fluid (CSF) levels; and (ii) to investigate whether increased MIF-related systemic and CNS inflammation is associated with clinical disease progression. METHODS: CSF and plasma concentrations of MIF as well as biomarkers of amyloid, neuronal injury, and tau hyperphosphorylation (CSF Aβ1-42, tau, and ptau, respectively) were assessed in 97 subjects with MCI or mild dementia (cognitive impairment, CI) and 52 healthy volunteers with normal cognition. Clinical and neuropsychological evaluations were performed at inclusion and at follow up visits. RESULTS: CSF MIF levels were higher in participants with CI with an AD CSF biomarker profile, but not in CI with a non-AD profile, compared to the healthy controls. Higher MIF CSF levels were associated with higher CSF tau and ptau and lower CSF Aβ1-42 after adjusting for potential confounders. In CI, MIF CSF independently predicted cognitive decline at a follow-up visit after controlling for potential confounders including CSF Aβ1-42 and tau levels. CONCLUSION: Our study provides evidence that MIF-related inflammation is related to amyloid pathology, tau hyperphosphorylation, and neuronal injury at the early clinical stages of AD. Higher MIF CSF levels are associated with accelerated cognitive decline in MCI and mild dementia.
Authors: Anna Morozova; Yana Zorkina; Olga Abramova; Olga Pavlova; Konstantin Pavlov; Kristina Soloveva; Maria Volkova; Polina Alekseeva; Alisa Andryshchenko; Georgiy Kostyuk; Olga Gurina; Vladimir Chekhonin Journal: Int J Mol Sci Date: 2022-01-22 Impact factor: 5.923
Authors: Mara Ten Kate; Alberto Redolfi; Enrico Peira; Isabelle Bos; Stephanie J Vos; Rik Vandenberghe; Silvy Gabel; Jolien Schaeverbeke; Philip Scheltens; Olivier Blin; Jill C Richardson; Regis Bordet; Anders Wallin; Carl Eckerstrom; José Luis Molinuevo; Sebastiaan Engelborghs; Christine Van Broeckhoven; Pablo Martinez-Lage; Julius Popp; Magdalini Tsolaki; Frans R J Verhey; Alison L Baird; Cristina Legido-Quigley; Lars Bertram; Valerija Dobricic; Henrik Zetterberg; Simon Lovestone; Johannes Streffer; Silvia Bianchetti; Gerald P Novak; Jerome Revillard; Mark F Gordon; Zhiyong Xie; Viktor Wottschel; Giovanni Frisoni; Pieter Jelle Visser; Frederik Barkhof Journal: Alzheimers Res Ther Date: 2018-09-27 Impact factor: 6.982
Authors: Anne T Kloek; Mercedes Valls Seron; Ben Schmand; Michael W T Tanck; Arie van der Ende; Matthijs C Brouwer; Diederik van de Beek Journal: Acta Neuropathol Commun Date: 2021-01-06 Impact factor: 7.801
Authors: Ana Carolina Alves Oliveira; Aline Dionizio; Francisco Bruno Teixeira; Leonardo Oliveira Bittencourt; Giza Hellen Nonato Miranda; Géssica Oliveira Lopes; Everton L P Varela; Mariane Nabiça; Paula Ribera; Kelly Dantas; Aline Leite; Marília Afonso Rabelo Buzalaf; Marta Chagas Monteiro; Cristiane Socorro Ferraz Maia; Rafael Rodrigues Lima Journal: Int J Mol Sci Date: 2020-09-21 Impact factor: 5.923